Skip to main content

Table 3 Prognostic factors for survival

From: Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan

Variable   Univariate logistic analysis Multivariate logistic analysis
N (%) OR 95 % Cl p-value OR 95 % Cl p-value
Age, years 209       
 <60 17 (8.1) ref    ref   
 60–69 52 (24.9) 1.12 0.374–3.362 0.839    
 70–79 98 (46.9) 1.83 0.647–5.196 0.254    
 ≥80 42 (20.1) 3.78 1.110–12.858 0.033 2.94 1.044–8.303 0.041
Male 172 (82.3) 1.41 0.681–2.930 0.354    
BMI, kg/m2 178       
 <18.5 27 (15.2) ref      
 18.5–25 114 (64.0) 1.43 0.604–3.388 0.415    
 >25 37 (20.8) 1.13 0.409–3.117 0.814    
Brinkman Index 184       
 0 68 (37.0) ref      
 1–800 45 (24.5) 1.37 0.617–3.046 0.439    
 >800 71 (33.6) 1.14 0.571–2.271 0.712    
F, H-J Classification scale 166       
 1–4 41 (24.7) ref    ref   
 5 125 (75.3) 2.53 1.229–5.187 0.012 2.13 0.931–4.856 0.073
Specialty hospital care 173 (82.8) 0.83 0.382–1.799 0.635    
Ambulance transfer 101 (48.3) 1.22 0.686–2.164     
Performing bronchoscopy 20 (9.6) 0.19 0.068–0.506 0.001 0.25 0.079–0.798 0.019
Sivelestat 104 (49.8) 0.87 0.489–1.538 0.626    
Diuretic drug 102 (48.8) 0.82 0.461–1.451 0.493    
Anticoagulant therapy 87 (41.6) 0.52 0.292–0.933 0.028    
Immunosuppressive therapy 75 (35.9) 0.66 0.366–1.193 0.17    
Intravenous high-dose cyclophosphamide 32 (15.3) 1.38 0.601–3.160 0.449 3.17 1.101–9.148 0.033
PMX 13 (6.2) 1.17 0.347–3.935 0.801    
Recombinant human soluble thrombomodulin 9 (4.3) 1.03 0.250–4.247 0.967    
Antibiotic therapy 206 (98.6)     
 β-Lactams 176 (84.2) 0.97 0.440–2.126 0.933    
 Co-trimoxazole 115 (55.0) 0.20 0.103–0.388 <0.001   0.28 0.132–0.607
 Quinolones 103 (49.3) 0.77 0.436–1.372 0.38    
 Macrolides 48 (23.0) 0.46 0.239–0.893 0.022   0.37 0.155–0.867
 Tetracycline 18 (8.6) 1.03 0.370–2.875 0.952    
 Anti-MRSA antibiotics 17 (8.1) 0.94 0.332–2.651 0.904    
 Clindamycin 5 (2.4) 0.33 0.054–2.042 0.235    
 Aminoglycoside 3 (1.4) 0.25 0.022–2.826 0.264    
 Others 12 (5.7) 0.71 0.216–2.307 0.564    
  1. Data are presented as n (%), unless otherwise indicated. Definition of abbreviations: BMI body mass index, F, H-J Fletcher, Hugh-Jones, PMX Direct hemoperfusion with polymyxin B-immobilized fiber, MRSA Methicillin-resistant Staphylococcus aureus